Warning: fopen(/home/virtual/colon/journal/upload/ip_log/ip_log_2025-01.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Precision medicine for primary rectal cancer will become a reality
Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Ann Coloproctol > Volume 38(4); 2022 > Article
Editorial
 Precision medicine for primary rectal cancer will become a reality
In Ja Park, M.D., Ph.D.orcid
Annals of Coloproctology 2022;38(4):281-282.
DOI: https://doi.org/10.3393/ac.2022.00500.0071
Published online: August 29, 2022

Department of Colon and Rectal Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence to: In Ja Park, M.D., Ph.D. Department of Colon and Rectal Surgery, Asan Medical Center, University of College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-3937, Fax: +82-2-474-9027 E-mail: ipark@amc.seoul.kr
• Received: July 12, 2022   • Accepted: July 13, 2022

Copyright © 2022 The Korean Society of Coloproctology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 2,281 Views
  • 120 Download
  • 6 Web of Science
  • 7 Crossref
  • 1 Scopus
Full Article

Download PDF Download PDF

Although precision medicine is the goal, in reality, rectal cancer treatment follows standard guidelines. Currently, the routine treatment for locally advanced rectal cancer includes neoadjuvant chemoradiotherapy and surgery, and this “one-size-fits-all” approach improves oncologic outcomes. However, bowel dysfunction, even in the case of sphincter preservation, has been an intractable problem and a major cause of worsening quality of life [1]. Therefore, there have been efforts to keep oncologic safety and improve quality of life as well in treatment of rectal cancer. The watch-and-wait approach which can preserve rectum has been used in a very small subset of patients who had complete clinical regression after neoadjuvant chemoradiotherapy. This approach presents a paradigm shift in rectal cancer treatment, making it a subject of great interest [2]. Intensifying multimodal neoadjuvant treatment accelerates the paradigm shift towards the watch-and-wait approach, i.e., surgery deferral [3].
Intensified neoadjuvant treatment relieves approximately 50% of patients from the functional deterioration of radical resection; however, it also causes dysfunction caused by chemoradiotherapy. The side effect of chemoradiotherapy is substantial and results in long-term discomfort. Although many studies have been conducted to address this problem, there is still no sufficient result that can help to reduce side effects. Indeed, patients who have mismatch repair–deficient rectal cancer may respond less to the current neoadjuvant treatment [4]. Therefore, these patients are prone to receive neoadjuvant therapy which might not be effective but toxic.
These patients have been targeted for immunotherapy, a game-changing treatment, because of their unique genetic properties. Therapeutic possibility of immunotherapy was studied and proved in the patients with metastatic colorectal cancer [5].
Cercek et al. [6] examined the therapeutic possibility of immunotherapy in rectal cancer treatment. In June, 12 patients with mismatch repair–deficient stage II or III rectal cancer were administered immunotherapy with dostarlimab, a programmed death 1 inhibitor. All patients who completed 6 months of dostarlimab treatment showed complete clinical regression upon magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, and endoscopy. All were free of tumor regrowth and other treatments during a median follow-up period of 1 year. The report is very promising because the treatment outcome was obtained without serious adverse events and further chemoradiotherapy. However, waiting for the long-term report is important because regrowth and distant metastasis can occur later on. Nevertheless, these patients have an increased potential to be cured without functional deterioration, which is common in the current treatment modality.
Aside from the insufficient follow-up period and small study population, the indication for treatment is also an issue. Although the authors included those with stage II and III rectal cancer, 25% of the patients had T1/T2 disease. These patients will have favorable outcomes even if they have lymph node metastasis with the current treatment strategy [7, 8]. In this regard, the proposed treatment strategy may change the disease status of these patients from curable to merely controllable. This necessitates reasonable and reliable response evaluation method and interval while considering both the clinical implication and medical cost.
Although only a short-term report, the study of Cercek et al. [6] is a step closer to precision medicine considering genetic and tumor status, as well as quality of life in 5% to 10% of patients with rectal cancer. Globally diverse clinical trial groups are needed to examine the possibility of using immunotherapy as a primary treatment for mismatch repair–deficient rectal cancer in the clinical setting.

CONFLICT OF INTEREST

In Ja Park has been editor-in-chief of the Annals of Coloproctology and was not involved in the review process of this editorial. Otherwise, there was no conflict of interest.

FUNDING

None.

  • 1. Eldamshety O, Kotb S, Khater A, Roshdy S, Elashry M, Zahi MS, et al. Early and late functional outcomes of anal sphincter-sparing procedures with total mesorectal excision for anorectal adenocarcinoma. Ann Coloproctol 2020;36:148–54.ArticlePubMedPMCPDF
  • 2. Huh JW, Maeda K, Liu Z, Wang X, Roslani AC, Lee WY. Current status of “watch-and-wait” rectal cancer treatment in Asia-Pacific countries. Ann Coloproctol 2020;36:70–7.ArticlePubMedPMCPDF
  • 3. Garcia-Aguilar J, Patil S, Kim JK, Yuval JB, Thompson H, Verheij F, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol 2020;38(15 Suppl):4008. Article
  • 4. Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res 2020;26:3271–9.ArticlePubMedPMCPDF
  • 5. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020;383:2207–18.ArticlePubMed
  • 6. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386:2363–76.ArticlePubMedPMC
  • 7. Mo S, Dai W, Xiang W, Huang B, Li Y, Feng Y, et al. Survival contradiction between stage IIA and stage IIIA rectal cancer: a retrospective study. J Cancer 2018;9:1466–75.ArticlePubMedPMC
  • 8. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 2010;28:256–63.ArticlePubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Performance reporting design in artificial intelligence studies using image-based TNM staging and prognostic parameters in rectal cancer: a systematic review
      Minsung Kim, Taeyong Park, Bo Young Oh, Min Jeong Kim, Bum-Joo Cho, Il Tae Son
      Annals of Coloproctology.2024; 40(1): 13.     CrossRef
    • Beyond survival: a comprehensive review of quality of life in rectal cancer patients
      Won Beom Jung
      Annals of Coloproctology.2024; 40(6): 527.     CrossRef
    • Unveiling the profound advantages of total neoadjuvant therapy in rectal cancer: a trailblazing exploration
      Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim, Donghyoun Lee, Chinock Cheong
      Annals of Surgical Treatment and Research.2023; 105(6): 341.     CrossRef
    • Preventing Anastomotic Leakage, a Devastating Complication of Colorectal Surgery
      Hyun Gu Lee
      The Ewha Medical Journal.2023;[Epub]     CrossRef
    • Influence of the COVID-19 Pandemic on the Treatment Patterns and Outcomes of Colorectal Cancer
      In Ja Park
      The Ewha Medical Journal.2023;[Epub]     CrossRef
    • How Can We Improve the Tumor Response to Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer?
      Jeonghee Han
      The Ewha Medical Journal.2023;[Epub]     CrossRef
    • Inflammatory Response Markers as Predictors of Colorectal Cancer Prognosis
      Minsung Kim, Il Tae Son, Bo Young Oh
      The Ewha Medical Journal.2023;[Epub]     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite this Article
      Cite this Article
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Precision medicine for primary rectal cancer will become a reality
      Ann Coloproctol. 2022;38(4):281-282.   Published online August 29, 2022
      DOI: https://doi.org/10.3393/ac.2022.00500.0071
      Close
    • XML DownloadXML Download
    Related articles
    Precision medicine for primary rectal cancer will become a reality
    Precision medicine for primary rectal cancer will become a reality
    Ann Coloproctol : Annals of Coloproctology Twitter Facebook
    © Korean Society of Coloproctology.
    TOP